Preresection Chemotherapy Improves Survival for Children With Askin Tumors
Robert S. Sawin, MD;
Ernst U. Conrad, III, MD;
Julie R. Park, MD;
John H. T. Waldhausen, MD
Arch Surg. 1996;131(8):877-880.
Abstract
Objective
To test whether patients with Askin tumor treated with aggressive neoadjuvant chemotherapy have a better clinical outcome.
Design
Retrospective case series.
Setting
Pediatric referral center.
Patients
All children diagnosed with malignant small-cell tumors of the chest wall (Askin tumor) and treated from 1975 to September 1987 (phase 1, n=6) and from September 1987 to the present (phase 2, n=9).
Main Outcome Measures
Survival as a function of extent of disease and response to therapy as measured by tumor volume, survival, and recurrence.
Results
All phase 2 patients had significant reduction of tumor volume and improved survival by Kaplan-Meier estimates compared with phase 1 patients. No phase 1 patients are still alive.
Conclusion
Patients with Askin tumor treated with aggressive preresection chemotherapy have smaller tumors to resect and improved survival.
Arch Surg. 1996;131:877-880
Author Affiliations
From the Departments of Surgery (Drs Sawin and Waldhausen), Orthopedic Surgery (Dr Conrad), and Pediatrics (Dr Park), Children's Hospital and Medical Center, University of Washington School of Medicine, Seattle.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Preoperative chemotherapy is essential for conservative surgery of Askin tumors
Veronesi et al.
J. Thorac. Cardiovasc. Surg. 2003;125:428-429.
FULL TEXT
Primitive neuroectodermal tumor of the pulmonary hilum in an adult
Baumgartner et al.
Ann. Thorac. Surg. 2001;72:285-287.
ABSTRACT
| FULL TEXT
|
